Coronavirus (COVID-19)
National and International Guidance Documents
Public Health Agency of Canada CORONAVIRUS HOTLINE 1-833-784-4397
Canadian and International guidelines, policies and standards that Infection Prevention and Control professionals may use to support their own documentation and best practices during the COVID-19 Pandemic.
Quick Index
- Government of Canada
- Guidance in Healthcare Settings
- COVID-19 Guidance During Pregnancy
- Laboratory and Supply Chain Guidance
- Guidance on Personal Protective Equipment and Alcohol-Based Hand Sanitizer
- Vaccine Guidance
- National Advisory Committee on Immunization (NACI)
- Public Health Guidance
- School and Community Guidance
- Awareness Resources
- Alerts, Recalls and Advisories
- CDC
- WHO
- APIC
- Other
Government of Canada
- COVID-19 Resources and Checklists (PHAC, Accreditation Canada and HSO)
- PHAC COVID-19 Vaccine Newsletter registration: HC-PHAC.PublicEducation-Educationpublique.SC-ASPC@hc-sc.gc.ca.
- SARS-CoV-2 variants: National definitions, classifications and public health actions
- Mathematical modelling and COVID-19
- Federal/Provincial/Territorial Public Health Response Plan for Ongoing Management of COVID-19
- Outbreak Update
- COVID-10 Symptoms and Treatments
- COVID-19 signs, symptoms and severity of disease: A clinician guide
- COVID-19: Main modes of transmission
- COVID-19 Prevention and risks
- Coronavirus disease (COVID-19): Canada’s Response
- COVID-19: Travel, testing and borders
- Chief Public Health Officer of Canada's Report on the State of Public Health in Canada 2020 -From risk to resilience: An equity approach to COVID-19
- Race-Based Data Collection and Health Reporting
- Pan-Canadian COVID-19 Response to COVID-19
- Pan-Canadian COVID-19 Testing and Screening Guidance: Technical guidance and implementation plan
- Pan-Canadian virtual care priorities in response to COVID-19
- Mental Illness during the Pandemic: Survey on COVID-19 and Mental Health
- COVID-19 and deaths in older Canadians: Excess mortality and the impacts of age and comorbidity
- Frequency and impact of longer-term symptoms following COVID-19 in Canadian adult
- Impact of COVID-19 in adults with chronic conditions: Emergency department visits
- Impacts of COVID-19 on Canadian nursing homes and seniors’ homes in 2021
- COVID-19 mortality among racialized populations in Canada and its association with income
- Unmet health care needs during the pandemic and resulting impacts among First Nations people living off reserve, Métis and Inuit
- Infographic: Examining how changes in alcohol and cannabis consumption varied by experiences of stigma during the COVID-19 pandemic in Canada
- Inequalities in the mental health of adults before and during the COVID-19 pandemic: data tool
COVID-19 Guidance in Healthcare Settings
- COVID-19 Pandemic Guidance for the Health Care Sector
- COVID-19 for Health Professionals
- COVID-19 Vaccination Tool Kit for Health Care Providers
- Infection prevention and control for COVID-19: Interim guidance for acute healthcare settings
- Update with Consideration of Omicron – Interim COVID-19 Infection Prevention and Control Government of Canada announces additional measures to contain the spread of the Omicron variant in the health care setting when COVID-19 is suspected or confirmed– December 23, 2021
- Infection prevention and control for COVID-19: Interim guidance for outpatient and ambulatory care settings
COVID-19 Guidance During Pregnancy
- Statement on Pregnant Workers during the COVID-19 Pandemic (SOGC)
- COVID-19 and Pregnancy (SOGC)
- Statement on COVID-19 Vaccination in Pregnancy (SOGC)
Laboratory and Supply Chain Guidance during the COVID-19 Pandemic
COVID-19 Guidance on Personal Protective Equipment (PPE) and Alcohol-Based Hand Sanitizer (ABHR)
- Non-medical Masks and Face Coverings
- Non-medical Masks -How to put on, remove and clean
- Non-medical Masks -Sew and no-sew instructions
- Use of Non-Medical Masks in Community Settings
- Non-medical masks or face coverings while travelling on public transportation
- How to safely use a non-medical mask or face covering (poster)
- How to wear a non-medical mask or face covering properly (video)
Vaccine Guidance
- COVID-19: How vaccines are developed
- Vaccine development and approval in Canada
- COVID-19 vaccine safety and side effects (information about Guillain-Barré syndrome
- Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age
- Regulatory Decision Summary: COVID-19 vaccine Moderna – Health Canada (12-17 years of age)
- Guidance for market authorization requirements for COVID-19 drugs: Overview
- COVID-19 Vaccine Communications Toolkit (Children, Youth and Young Adults)
- Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis)
- Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: Overview
- Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age
- Details for: COVIFENZ - COVID-19
- Health Canada authorizes use of the Moderna Spikevax (50 mcg) COVID-19 vaccine in children 6 to 11 years of age
- Health Canada authorizes Pfizer-BioNTech COVID-19 vaccine for children six months to four years of age
- Statement from the Council of Chief Medical Officers of Health (CCMOH) on vaccination programs for Fall 2022
- Health Canada authorized the Pfizer-BioNTech Comirnaty® Original and Omicron BA.1, bivalent COVID-19 booster vaccine for use in individuals 12 years of age and olde
- Health Canada authorizes second bivalent COVID-19 booster targeting the Omicron BA.4/5 variants
National Advisory Committee on Immunization (NACI)
- NACI Preliminary guidance on key populations for early COVID-19 immunization
- NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series
- NACI rapid response: Booster dose in long-term care residents and seniors living in other congregate settings
- NACI: Recommendations on the use of COVID-19 Vaccines
- NACI Statement: Interim guidance on booster COVID-19 vaccine doses in Canada
- NACI Statment: Recommendations on the use of COVID-19 vaccines
- NACI: Summary of the updated vaccine statement -MRNA COVID-19 Vaccines and Myocarditis
- NACI Statement: Interim guidance on booster COVID-19 vaccine doses in Canada
- NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
- Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age (NACI)
- NACI: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply
- NACI: Summary of Extended Dose Intervals Statement of April 7, 2021
- NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults
- Summary of the NACI Statement -Recommendation on the use of the PfizerBioNTech COVID-19 Vaccine in children 5-11 years of age
- NACI Rcommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age
- NACI Statement: Rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2
- NACI Summary: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2
- NACI Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine (PDF)
- Summary of the NACI statement of February 17, 2022
- Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis)
- NACI Statement: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz
- Summary of the NACI statement of March 11, 2022
- NACI Statement: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age
- Summary of the NACI statement of March 17, 2022
- NACI Statement: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age
- Summary of NACI statement of July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age
- Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada
- Summary of NACI of June 29, 2022 -Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada
- NACI Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age
- NACI Summary: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age
- NACI Statement: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding
- NACI Summary: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding
- NACI Statement: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age
- NACI Summary: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age
- Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults
- Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults
- Summary of NACI statement of December 9, 2022
- NACI Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration
COVID-19 Awareness Resources
-
Coronavirus disease (COVID-19): Awareness resources (Posters and Videos)
-
Coronavirus disease (COVID-19): Information sheet - Travellers returning to Canada (includes contact information for public health authorities in each province and territory)
- Novel Coronavirus infection: Frequently Asked Questions (FAQ)
- People who are at risk of more severe disease or outcomes from COVID-19
- COVID-19 antibody (serology) testing: Information for patients
- COVID-19: We're doing this for this (closed captions in other languages)
- COVID-19: How vaccines are developed
- Vaccine development and approval in Canada
- People who are at risk of more severe disease or outcomes from COVID-19
Alerts, Recalls and Advisories
2022
- Dec 9: COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels: New Formulation for Use in Children Aged 5 Years to Less Than 12 Years
- Nov 20: SPIKEVAX Bivalent (Original / Omicron BA.4/5) (elasomeran/davesomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
- Oct 26: EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
- Oct 7: COMIRNATY Original & Omicron BA.4/BA.5 Bivalent Vaccine with English-only Vial and Carton Labels
- Sep 12: Health Canada warns about certain hand sanitizers that may pose health risks
- Sep 9: COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Presentation for Use in Children Aged 6 Months to Less Than 5 Years with English-only Vial and Carton Labels
- Sep 2: Distribution of SPIKEVAX Bivalent (elasomeran/imelasomeran) COVID-19 Vaccine with English-only Vial and Carton Labels
- Aug 15: Sanitizer: Contains undeclared impurity at elevated levels
- Aug 5: Counterfeit COVID-19 antigen rapid test kits found in Ontario
- Jul 28: Apotex recalls Apo-Acyclovir tablets due to a nitrosamine impurity
- Jul 11: Health Canada warns about certain hand sanitizers that may pose health risks (Part 2 – March 31, 2021 to present)
- Jul 6: PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
- Jun 23: GOJO Canada Inc. recalls a lot of Purell Hand Sanitizing Wipes (Canada-wide) RECALL
- June 16: Rocky Mountain Soap Company recalls hand sanitizers due to the potential presence of undeclared methanol
- May 9: COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Formulation/Presentation for Use in Individuals 12 Years of Age and Older
- Jan 17: Important Safety Information on PAXLOVID (nirmatrelvir and ritonavir) Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels -Pfizer Canada UL
- Jan 7/22: Casirivimab and Imdevimab – High Risk of Treatment Failure Due to Circulation of SARS-CoV-2 Omicron Variant
2021
- July 11: Health Canada warns about certain hand sanitizers that may pose health risks (Part 2 – March 31, 2021 to present)
- July 6: PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
- Nov 19: COMIRNATY (COVID-19 Vaccine, mRNA, also referred to as Pfizer-BioNTech COVID-19 Vaccine): New Formulation for Use in Children Aged 5 Years to Less Than 12 Years
- Oct 22: Health Canada warns about certain hand sanitizers that may pose health risks
- Oct 19: Ivermectin not authorized to prevent or treat COVID-19; may cause serious health
- Oct 8: Health Canada warns about certain hand sanitizers that may pose health risk
- Sept 23: Health Canada suspends licence and requested a recall for PURE75 gel hand sanitizer due to potential serious health risks
- Sept 14: Recall of certain hand sanitizers that may pose health risks
- Aug 24: Recall of certain hand sanitizers that may pose health risks
- Aug 6: Health Canada updates Pfizer-BioNTech COVID-19 vaccine label to reflect very rare reports of Bell's Palsy
- Jul 13: Update: Graphene face masks by Shandong Shengquan New Materials Co. Ltd. can resume sale in Canada; Health Canada found no health risks of concern with these
- Jul 12: Recall of certain hand sanitizers that may pose health risks
- Jun 30: Health Canada updates Pfizer-BioNTech and Moderna COVID-19 vaccine labels to include information on myocarditis and pericarditis
- Jun 29: AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome
- Jun 22: Recall of certain hand sanitizers that may pose health risks
- May 12: Natural Concepts Sanitizing Gel
- May 10: Recall of certain hand sanitizers that may pose health risks
- Apr 28: Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant SARS-CoV-2 Variants
- Apr 26: Janssen COVID-19 Vaccine and the Risk of Thrombosis with Thrombocytopenia
- Apr 26: Importation of Janssen COVID-19 Vaccine with Two Types of English-only Vial and Carton Labels
- Apr 19: Recall of certain hand sanitizers that may pose health risks
- Apr 14: Health Canada provides update on the AstraZeneca and COVISHIELD COVID-19 vaccines
- Apr 2: Face masks that contain graphene may pose health risks
- Mar 31: Importation of AstraZeneca COVID-19 Vaccine with English-only Vial and Carton Labels (US-Labelled Supply)
- Mar 24: Recall of certain hand sanitizers that may pose health risks
- Mar 24: AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia
- Mar 19: Counterfeit 3M N95 respirators
- Mar 15: Recall of certain hand sanitizers that may pose health risks
- Mar 11: Adverse events in Europe following immunization with the AstraZeneca COVID-19 vaccine
- Mar 8: Pfizer-BioNTech COVID-19 Vaccine: Updated Storage and Transportation Conditions
- Mar 8: Authorization of Janssen COVID-19 Vaccine with English-only Vial and Carton Labels
- Feb 22: COVID-19 Vaccine Moderna: Updated English-only Global Vial and Carton Labels and Post-Market Adverse Reaction Information
- Feb 17: Recall of certain hand sanitizers that may pose health risks
- Feb 9: Important Safety Information on Pfizer-BioNTech COVID-19 Vaccine: Updated Dosage and Administration and Post-Market Adverse Reaction Information - Pfizer Canada ULC
- Feb 8: Unauthorized hand sanitizers and hard surface disinfectants sold by Protegel Quebec Inc. and Hangel Canada Inc. may pose health risks
- Feb 3: Recall of certain hand sanitizers that may pose health risks
- Jan 29: Testing confirms Bio Life hand sanitizer poses health risks; products recalled across Canada
- Jan 22: Hand sanitizers labelled as "Anti-Microbe" and/or with DIN 02248351 recalled because they may pose health risks, particularly to children
2020
- Dec 23: Authorization of Moderna COVID-19 Vaccine with English-only Vial and Carton Labels
- Dec 22: Personal protective equipment sold by Maskopia (formerly Medkem Canada Inc.) may pose serious health risks
- Dec 16: Health Canada warns Canadians not to buy COVID-19 vaccines sold online or from unauthorized sources
- Dec 12: Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies
- Dec 11: Recall of certain hand sanitizers that may pose health risks
- Nov 18: Ultraviolet (UV) lights and wands falsely claiming to disinfect against COVID-19
- Nov 13: Recall of certain hand sanitizers that may pose health risks
- Nov 2: Recall of certain hand sanitizers that may pose health risks
- Oct 28: Recall of Daily Shield Hand Sanitizers across Canada
- Oct 19: Recall of certain hand sanitizers that may pose health risks
- Oct 18: Counterfeit Daily Shield Hand Sanitizer
- Oct 13: Recall of certain hand sanitizers that may pose health risks
- Sep 28: Recall of certain hand sanitizers that may pose health risks
- Sept 15: Importation of US Clinical Trial-Labelled Remdesivir for Injection Due to Shortage of Canadian-Labelled Remdesivir
- Sept 14: Recall of certain hand sanitizers that may pose health risks
- Sep 4: Advisory on hand sanitizers and children’s safety: What you need to know
- Sep 4: Recall of certain hand sanitizers that may pose health risks
- Aug 21: Recall of certain hand sanitizers that contain technical-grade ethanol
- Aug 4: Recall of certain hand sanitizers that may pose health risks
- Jul 28: Remdesivir authorized with conditions for the treatment of patients in Canada with severe COVID-19 symptoms
- Jul 21: Recall of certain hand sanitizers that may pose health risks
- Jul 6: Counterfeit respirators
- Jun 30: Recall of certain hand sanitizers that may pose health risks
- Jun 24: Recall of certain hand sanitizers that contain technical-grade ethanol
- Jun 10: Risk of poisoning from hand sanitizers sold in beverage containers
- Jun 6: Recall of certain hand sanitizers that may pose health risks
- Jun 1: Health Canada advises Canadians to help support the continued supply of medications
- May 27: Consumers advised to stop using Akwaton International Multipurpose Wipes
- May 27: Some units of Triton Hand Sanitizer containing technical-grade ethanol sold in Canada without the necessary risk information
- May 25: Importation of US-Labelled Rocuronium Bromide Injection distributed by Avir Pharma Inc. Due to Shortage of Canadian-labelled Rocuronium
- May 19: Importation of Fresenius Propoven 2% due to Shortage of Canadian Labelled Propofol Injection 1% Products
- May 19: Importation of Spanish-Labelled Salbutamol Aldo-Union inhalers due to Shortage of Canadian-Labelled Salbutamol
- May 13: Important Safety Information - Importation of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler due to Shortage
- May 11: Important safety information for certain respirator masks
- May 7: Unauthorized test kits claiming to diagnose or detect COVID-19 put your health at risk
- May 6: Importation of US-Labelled Ketamine Hydrochloride for Injection due to Potential Shortage of Canadian-labelled Ketamine
- May 1: Clinical trial looking at the potential use of convalescent plasma to treat COVID-19
- Apr 25: Chloroquine and hydroxychloroquine can have serious side effects. These drugs should be used only under the supervision of a physician
- Apr 17: Shortage of salbutamol inhalers in Canada
- Apr 15: Health Canada is temporarily authorizing the use of technical-grade ethanol in hand sanitizer products: Always follow the label directions when using alcohol-based hand sanitizers
- Apr 14: Fraudulent and unauthorized N95 respirators may not protect consumers against COVID-19
Centers for Disease Control and Prevention
- CDC - Coronavirus COVID-19
- How COVID-19 Spreads
- Information for Healthcare Professionals about Coronavirus (COVID-19)
- Infection Control Guidance for Healthcare Professionals about Coronavirus (COVID-19)
- Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus (COVID-19) in a Healthcare Setting
- CDC Situation Summary
- New Variants of the Virus that Causes COVID-19
- Interim Guidance for Public Health Personnel Evaluating Persons Under Investigation (PUIs) and Asymptomatic Close Contacts of Confirmed Cases at Their Home or Non-Home Residential Settings
- Interim Guidance for Collection and Submission of Postmortem Specimens from Deceased Persons Under Investigation (PUI) for COVID-19, February 2020
- Evaluating and Reporting Persons Under Investigation (PUI)
- Strategies for Optimizing the Supply of PPE
- Release of Stockpiled N95 Filtering Facepiece Respirators Beyond the Manufacturer-Designated Shelf Life: Considerations for the COVID-19 Response
- Decontamination and Reuse of Filtering Facepiece Respirators using Contingency and Crisis Capacity Strategies
- Healthcare Infection Control Guidance
- Healthcare Personnel with Potential Exposure Guidance
- Inpatient Obstetric Healthcare Guidance
- Clinical Care Guidance
- Nursing Homes and Long-Term Care Facilities (CDC)
- Home Care Guidance
- Considerations for Alternate Care Sites
- Guidance for EMS
- Guidance for Dental Settings (CDC)
- Collection and Submission of Postmortem Specimens from Deceased Persons with Known or Suspected COVID-19, March 2020 (Interim Guidance)
- Use of Cloth Face Coverings to Help Slow the Spread of COVID -19
- Options to Reduce Quarantine for Contacts of Persons with SARS-CoV-2 Infection Using Symptom Monitoring and Diagnostic Testing
- Interim Public Health Recommendations for Fully Vaccinated People
- COVID-19 Vaccination for Pregnant People to Prevent Serious Illness, Deaths, and Adverse Pregnancy Outcomes from COVID-19
World Health Organization/Organisation mondiale de la santé
- WHO -Coronavirus COVID-19 Outbreak
- COVID-19 Global Cases (WHO)
- Transmission of SARS-CoV-2: implications for infection prevention precautions
- WHO Online Course: Infection Prevention and Control (IPC) for Novel Coronavirus (COVID-19)
- WHO Rational use of personal protective equipment for coronavirus disease (COVID-19)
- Coronavirus disease (COVID-19) technical guidance: Infection prevention and control
- Criteria for releasing COVID-19 patients from isolation
- WHO Rational use of personal protective equipment for coronavirus disease (COVID-19)
- Novel coronavirus (COVID-19) Video
- Situation Reports
- Outbreak News
- WHO Disease Outbreak News (Jan 21/20)
Association for Professionals in Infection Control and Epidemiology
European Centre for Disease Control
- Algorithm for management of contacts of probable or confirmed COVID-19 cases
- Advice to healthcare workers: management of patients with COVID-19 infection
- Advice for travellers: outbreak of a novel coronavirus COVID-19
- Risk assessment: outbreak of acute respiratory syndrome associated with a novel coronavirus
Other Guidelines
- COVID-19 Resources (Canadian Nurses Association)
- COVID-19 Recommendations (Choosing Wisely)
- COVID-19: Recommendations for School Reopening (Sick Kids)
- COVID-19 and Pregnancy (SOGC)
- Briefing Note on Addressing Mental Health and Psychosocial Aspects of COVID-19 Outbreak (United Nations Office for the Coordination of Humanitarian Affairs)
- National Interim Guidelines for Funeral Directors on managing infection risks when handling deceased individuals with confirmed COVID-19 (Health Protection and Surveillance Centre)
- ASHRAE Position Document on Infectious Aerosols (ASHRAE)
- Policy Guidance for the Reintegration of Caregivers as Essential Care Partners (CFHI & CPSI)
- Statement on COVID-19 Vaccination in Pregnancy (SOGC)
- Statement on Pregnant Workers during the COVID-19 Pandemic (SOGC)
- Recommendations on the use of COVID-19 Vaccines
- Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age (NAC)
Dentistry
- Evidence to support safe return to clinical practice by oral health professionals in Canada during the COVID-19 pandemic: A report prepared for the Office of the Chief Dental Officer of Canada (PHAC)
- COVID-19 (Canadian Dental Association)
- COVID-19 (Canadian Dental Hygienists Association)
- COVID-19: Managing Infection Risks During In-Person Dental Care (Royal College of Dental Surgeons of Ontario)
- COVID-19: Guidance for the Use of Teledentistry (Royal College of Dental Surgeons of Ontario)
- COVID-19: Guidance on Returning to Dental Hygiene Practice (College of Dental Hygenists of Ontario)
- COVID-19 Recommendations (Canadian Dental Assistants Association)
- Recommendations for Dental Hygienists and Canadian Dental Assistants During COVID-19 Outbreak (Canadian Dental Assistants Association)
- Transitioning Oral Healthcare to Phase 2 of the COVID-19 Response Plan (BC College of Dental Surgeons/College of Dental Hygienists of BC)
- Expectations and Pathway for Patient Care during the COVID-19 Pandemic (Alberta Dental Association & College)
- Interim IPC Guidelines Related to COVID-19 Management (Manitoba Dental Association
- COVID-19 Operational Plan for the Practice of Dentistry in the Province of New Brunswick (New Brunswick Dental Association
- Pandemic Plan COVID-19 For Emergency and Urgent Care (Newfoundland and Labrador Dental Association)
- COVID-19: Managing Infection Risks During In-Person Dental Care (Royal College of Dental Surgeons of Ontario)
- COVID-19 Pandemic: Level 2 IPC Interim Protocol Update (Saskatchewan College of Dental Surgeons)
- Guidance for Dental Settings (CDC)
Prevention & Management of Skin Damage Related to PPE (NSWOCC and CNA)
- Prevention & Management of Skin Damage Related to Personal Protective Equipment (PPE)
- Best practice recommendation document
- Quick Reference Enabler
- Educational video
- Teaching powerpoint